Business Wire

GLOBAL-DAIRY-PLATFORM

11.11.2022 01:02:43 CET | Business Wire | Press release

Share
Dairy Sector Reports Progress on Global Pathways to Dairy Net Zero Climate Initiative at COP27

The dairy sector today announced progress of its global Pathways to Dairy Net Zero (P2DNZ) climate initiative, which was launched last year. The ground-breaking effort is achieving positive results in many regions and accelerating action in others, according to speakers at a COP27 side event, “The Global Dairy Sector’s Climate Ambition and Progress Towards Achievement of the Paris Agreement.”

P2DNZ is backed by more than 140 leading organizations and governments, including the 10 largest dairy companies in the world. Collectively, supporters represent more than 40% of global dairy production throughout the supply chain, making it one of the largest initiatives of its kind in agriculture.

“Dairy is a major force for good in the world, especially when you consider how the sector helps provide important nutrition to the hungry and malnourished and helps build strong, resilient economies, said Hein Schumacher, chair of Global Dairy Platform, one of the founders of Pathways to Dairy Net Zero, and CEO of Royal FrieslandCampina. “By systematically introducing and enhancing climate action in global dairy systems, dairy is tackling the challenge and making progress in reducing our impact on the planet,” he said.

Research is Identifying Practical Pathways for Dairy Systems Worldwide
Research commissioned as part of P2DNZ has identified six primary dairy production systems throughout the world, along with potential mitigation options and their estimated impact on emissions reduction. The research is led by the Global Research Alliance on Agricultural Greenhouse Gases (GRA) in close collaboration with the UN Food and Agriculture Organization (FAO). They have defined the composition of GHGs emitted by the various dairy production systems around the world and learned there is variability by system. For instance, methane is a large proportion of GHGs in pastoral and agropastoral systems, driven largely by enteric fermentation. However, high-input, high-output production emits a different mix of GHGs from not only enteric fermentation but also manure management, animal feed and energy use.

The six dairy production systems include:

  • High-input, high-output
  • Medium-scale specialized
  • Pasture-fed
  • Smallholder specialized
  • Smallholder dual-purpose
  • Pastoral and agropastoral

Researchers are also modeling the impact on warming of cumulative emissions for each GHG. This work is critical because each gas has a different effect and unique longevity in the atmosphere. For instance, while methane is a highly potent GHG it breaks down in the atmosphere in 12 years. Whereas other gases, such as carbon dioxide, can remain in the atmosphere for hundreds of years.

Although mitigation options will vary by each dairy production system, some of the primary pathways include improving animal health, increasing feed digestibility, enhanced manure storage and treatment, more efficient fertilizer use and the potential adoption of methane-inhibiting feed additives.

“Because GRA brings together leading expertise in agricultural GHG emissions, we are pleased to be working on the Pathways to Dairy Net Zero initiative to map emissions and mitigation potential within the diverse range of global dairy production systems,” said Dr. Harry Clark, co-chair of the Livestock Research Group of GRA and co-director of the New Zealand Agricultural Greenhouse Gas Research Centre. “While there are good options emerging for dairy systems in developed countries, our analysis reinforces the importance of developing and implementing appropriate options for regions and systems where the climate, soil and access to markets have limited options,” he said.

Progress in Developed Markets
Dairy companies around the world are reducing their impacts on the environment by improving farming and production practices and developing new technologies. FAO reports that during the period from 2005 – 2015, the global dairy sector’s emission intensity declined by 11%. Dairy farming has become more efficient which is resulting in declining emission intensities per unit of product all over the world. This is especially true in developed dairy markets where emission intensities have declined to between 1.3 to 1.4 kg CO₂ equivalent kg fat-and-protein corrected milk. For comparison, developing dairy regions’ emission intensities can range between 4.1 to 6.7 kg CO₂ equivalent per kg fat-and-protein corrected milk.

Tackling Emissions in Emerging Markets
Many of the best practices that have already been developed are being implemented in emerging dairy countries, where approximately 80% of the global dairy sector’s emissions are generated.

To help facilitate and accelerate these efforts, the global dairy sector, the Global Methane Pledge, FAO and others have invited 10 developing dairy countries to join P2DNZ as “early adopters.” Collectively these countries represent more than 30% of the sector’s global GHG emissions and include (those in bold have already accepted):

  • Africa: Tanzania, Kenya, Rwanda, Uganda
  • Americas: Uruguay, Costa Rica, Colombia
  • Asia: Pakistan, Vietnam, India

For more information, or to join Pathways to Dairy Net Zero, visit: www.pathwaystodairynetzero.org.

###

About Pathways to Dairy Net Zero
Pathways to Dairy Net Zero is a vibrant, growing movement, the first of its kind in the world. It brings together dairy systems of every size and type, including organizations throughout the dairy supply chain.

Partners include: Global Dairy Platform, International Dairy Federation, Sustainable Agriculture Initiative Platform, International Livestock Research Institute, Dairy Sustainability Framework and IFCN Dairy Research Network.

The Global Research Alliance on Agricultural Greenhouse Gases is a knowledge partner.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005906/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye